Fapon Biopharma's Anti-CD47 Antibody FP002 Earns IND Approval from FDA
- Written by PR Newswire
SHENZHEN, China, Feb. 22, 2023 /PRNewswire/ -- Fapon Biopharma, an innovative biotech company, announced today that its Investigational New Drug (IND) application of FP002, an anti-CD47 monoclonal antibody drug candidate, has been approved by FDA for clinical trials.
FP002 is a humanized anti-CD47 IgG4 monoclonal antibody, developed and...
Read more: Fapon Biopharma's Anti-CD47 Antibody FP002 Earns IND Approval from FDA














